UA92670C2 - Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе - Google Patents

Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе

Info

Publication number
UA92670C2
UA92670C2 UAA200903302A UAA200903302A UA92670C2 UA 92670 C2 UA92670 C2 UA 92670C2 UA A200903302 A UAA200903302 A UA A200903302A UA A200903302 A UAA200903302 A UA A200903302A UA 92670 C2 UA92670 C2 UA 92670C2
Authority
UA
Ukraine
Prior art keywords
receptor antagonists
composition based
pharmaceutical use
mineralocorticoid receptor
pyrazoline compounds
Prior art date
Application number
UAA200903302A
Other languages
English (en)
Ukrainian (uk)
Inventor
Марвин Джей Мейэрс
Гресиэла Барбиэри Аргансет
Киянгйан Чен
Сюзан Ландис Гокерман
Скотт Аллен Лонг
Метью Виллиям Махони
Девид Брюс Рейтс
Джозеф Герас Рико
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of UA92670C2 publication Critical patent/UA92670C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA200903302A 2006-10-31 2007-10-17 Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе UA92670C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86360606P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
UA92670C2 true UA92670C2 (ru) 2010-11-25

Family

ID=39027523

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200903302A UA92670C2 (ru) 2006-10-31 2007-10-17 Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе

Country Status (40)

Country Link
US (3) US7781428B2 (ru)
EP (1) EP2089367B1 (ru)
JP (1) JP4977760B2 (ru)
KR (1) KR101107800B1 (ru)
CN (1) CN101541757A (ru)
AP (1) AP2527A (ru)
AR (1) AR063529A1 (ru)
AT (1) ATE537151T1 (ru)
AU (1) AU2007315884B2 (ru)
BR (1) BRPI0717937A2 (ru)
CA (1) CA2667966C (ru)
CL (1) CL2007003154A1 (ru)
CO (1) CO6160307A2 (ru)
CR (1) CR10725A (ru)
CU (1) CU23779B7 (ru)
CY (1) CY1112311T1 (ru)
DK (1) DK2089367T3 (ru)
EA (1) EA016370B1 (ru)
ES (1) ES2375877T3 (ru)
GE (1) GEP20115239B (ru)
GT (1) GT200700096A (ru)
HN (1) HN2007000437A (ru)
HR (1) HRP20120078T1 (ru)
IL (1) IL198241A0 (ru)
MA (1) MA30821B1 (ru)
MX (1) MX2009004662A (ru)
MY (1) MY145795A (ru)
NI (1) NI200900071A (ru)
NO (1) NO20091741L (ru)
NZ (1) NZ575923A (ru)
PE (1) PE20081472A1 (ru)
PL (1) PL2089367T3 (ru)
PT (1) PT2089367E (ru)
RS (2) RS52203B (ru)
SI (1) SI2089367T1 (ru)
TN (1) TN2009000160A1 (ru)
TW (1) TWI357327B (ru)
UA (1) UA92670C2 (ru)
UY (1) UY30670A1 (ru)
WO (1) WO2008053300A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
JP2013528598A (ja) 2010-05-11 2013-07-11 ファイザー・インク ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
WO2012048022A2 (en) * 2010-10-05 2012-04-12 Nova Southeastern University Methods and compositions for therapeutic modulation of aldosterone levels in heart disease
AU2015282450C1 (en) 2014-06-30 2018-09-20 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JP7029445B2 (ja) 2016-09-02 2022-03-03 ブリストル-マイヤーズ スクイブ カンパニー 置換された三環式ヘテロ環化合物
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company OXIME ETHER COMPOUNDS
CN109051490A (zh) 2018-09-18 2018-12-21 深圳市鲸仓科技有限公司 可移动式密集存拣装置
EP4118235A1 (en) 2020-03-11 2023-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN113679716B (zh) 2021-10-13 2024-03-26 史大永 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) * 2022-01-04 2023-06-09 中山大学 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086068A (en) 1964-09-02 1967-10-04 Ici Ltd Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) 1988-09-30 1989-09-12 Eastman Kodak Company Thermally-transferable fluorescent diphenylpyrazolines
US5550152A (en) 1992-01-23 1996-08-27 Pfizer Inc. Benzopyran and related LTB4 antagonists
GB9318691D0 (en) 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
CA2263586A1 (en) * 1996-09-05 1998-03-12 Eifion Phillips Novel aryl-pyridazines
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
DE69918542T2 (de) 1998-04-30 2005-08-18 Abbott Gmbh & Co. Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
US6432974B1 (en) 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2006508893A (ja) 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−2−オン誘導体
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
JP4733388B2 (ja) 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Gsk−3のインヒビターとして有用なピラゾール組成物
MXPA05002376A (es) 2002-09-18 2005-05-23 Pfizer Prod Inc Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf).
CN1742007A (zh) 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
CN1918151A (zh) * 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
JP4703649B2 (ja) 2004-07-30 2011-06-15 エグゼリクシス, インコーポレイテッド 薬学的因子としてのピロール誘導体
AU2006205220B2 (en) 2005-01-10 2012-09-13 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
EP1844768A1 (en) 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatic sulfone compound as aldosterone receptor modulator
CN101115745A (zh) 2005-02-10 2008-01-30 默克公司 有丝分裂驱动蛋白抑制剂

Also Published As

Publication number Publication date
PL2089367T3 (pl) 2012-04-30
US20100280016A1 (en) 2010-11-04
ATE537151T1 (de) 2011-12-15
WO2008053300A1 (en) 2008-05-08
CR10725A (es) 2009-05-12
CO6160307A2 (es) 2010-05-20
HRP20120078T1 (hr) 2012-02-29
DK2089367T3 (da) 2012-02-06
EA200970341A1 (ru) 2009-10-30
EP2089367A1 (en) 2009-08-19
PT2089367E (pt) 2012-02-01
TWI357327B (en) 2012-02-01
PE20081472A1 (es) 2008-10-18
IL198241A0 (en) 2009-12-24
TN2009000160A1 (fr) 2010-10-18
CN101541757A (zh) 2009-09-23
US20080167294A1 (en) 2008-07-10
AP2527A (en) 2012-12-06
AR063529A1 (es) 2009-01-28
HN2007000437A (es) 2011-01-17
AU2007315884A1 (en) 2008-05-08
ES2375877T3 (es) 2012-03-07
RS52203B (en) 2012-10-31
RS20090208A (en) 2010-06-30
TW200822924A (en) 2008-06-01
MA30821B1 (fr) 2009-10-01
NO20091741L (no) 2009-05-29
GT200700096A (es) 2010-07-15
NZ575923A (en) 2011-01-28
MY145795A (en) 2012-04-30
KR101107800B1 (ko) 2012-01-25
GEP20115239B (en) 2011-06-10
AP2009004822A0 (en) 2009-04-30
JP2010508257A (ja) 2010-03-18
SI2089367T1 (sl) 2012-02-29
US7781428B2 (en) 2010-08-24
UY30670A1 (es) 2008-05-31
JP4977760B2 (ja) 2012-07-18
MX2009004662A (es) 2009-05-22
CU20090058A7 (es) 2011-07-11
KR20090060371A (ko) 2009-06-11
BRPI0717937A2 (pt) 2013-12-03
EP2089367B1 (en) 2011-12-14
EA016370B1 (ru) 2012-04-30
US20120035131A1 (en) 2012-02-09
CY1112311T1 (el) 2015-12-09
CL2007003154A1 (es) 2008-05-09
AU2007315884B2 (en) 2012-10-04
NI200900071A (es) 2010-03-08
CA2667966C (en) 2011-08-02
CA2667966A1 (en) 2008-05-08
CU23779B7 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
HK1120442A1 (en) Novel opioid antagonists
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
ATE483707T1 (de) 2-cyclopropylthiazolderivate
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
TW200745122A (en) New compounds I
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
WO2008074803A3 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
EP2238105A4 (en) NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
WO2009076408A3 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
TW200745133A (en) New compounds II